RMD ResMed

Q1 2025 10-Q

Filed: Apr 24, 2025Period ending Mar 31, 2025

Health Care

Surgical & Medical Instruments & ApparatusSEC EDGAR

ResMed (RMD) 10-Q quarterly report for Q1 2025, filed with SEC EDGAR on Apr 24, 2025 for the fiscal period ending Mar 31, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.

AI Filing Analysis
Q1 2025 10-Q

Risk Factors

• New risk: U.S. tariffs on imports from Canada, Mexico, China triggered retaliatory trade measures impacting sourcing costs and revenue
• Updated macroeconomic risk: Recent Red Sea shipping disruptions added to inflation, currency, and capital market volatility affecting supply chain and demand

+3 more insights

Quarterly Financial Summary
XBRL

Revenue

$1.2B

Net Income

$311M

Net Margin

25.4%

Source: XBRL data from ResMed Q1 2025 10-Q filing on SEC EDGAR. All figures in USD.

Other ResMed Quarterly Reports

Q4 2025 10-Q

Q3 2025 10-Q

Get deeper insights on ResMed

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.